Skip to main content
. 2021 May 20;8(6):1343–1352. doi: 10.1002/acn3.51373

Table 1.

Patient demographics.

Characteristic

Placebo

(n = 27)

Luvadaxistat

75 mg BID

(n = 14)

Luvadaxistat

300 mg BID

(n = 26)

Mean age at screening, years (SD) 32.5 (11.0) 31.1 (11.3) 29.6 (8.9)
Sex, n (%)
Female 17 (63.0) 5 (35.7) 15 (57.7)
Male 10 (37.0) 9 (64.3) 11 (42.3)
Mean body mass index, kg/m2 (SD) 24.9 (4.9) 24.9 (4.4) 23.0 (3.9)
Ambulation status, n (%)
Ambulatory 12 (44.4) 6 (42.9) 12 (46.2)
Non‐ambulatory 15 (55.6) 8 (57.1) 14 (53.8)

BID, twice daily; SD, standard deviation.